Skip to main content
Premium Trial:

Request an Annual Quote

Applied Markets Watch: Roche MycoTool

Premium

Roche said this week that the Canadian Health Authority has accepted the use of its PCR-based mycoplasma detection test MycoTool for release testing of an undisclosed Roche biological product.

Roche said that the test can replace conventional and time-consuming mycoplasma detection assays based on culture methods. The assay was accepted by the US Food and Drug Administration late last year for release testing of an undisclosed Roche biopharmaceutical product (PCR Insider, 12/20/2012).

Mycoplasms are frequent causes of contamination in biopharmaceutical production, cell therapy, tissue engineering and vaccine manufacturing. Traditional detection methods use growth on culture media and in vitro assays to detect contaminating organisms. These growth-based methods require as many as 28 days to complete, are laborious, and difficult to interpret, Roche said.

The MycoTool PCR kit provides all critical reagents for sample preparation and PCR. It offers sensitivity of less than 1 colony-forming unit/ml for most isolates and is compatible with a diverse spectrum of sample types including primary and continuous human cells, canine cells, nonhuman primate cells, many different rodent cell types, and cell-free matrices (culture supernatants of CHO or human stem cells, and egg-derived samples). The assay also detects the broad panel of Mollicute species due to universal primer design.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.